Roche Holding AG (OTCQX:RHHBY) Q4 2024 Earnings Conference Call January 30, 2025 8:00 AM ET
Company Participants
Thomas Schinecker – CEO
Alan Hippe – Chief Financial & Information Officer
Teresa Graham – CEO, Roche Pharmaceuticals
Matt Sause – CEO, Roche Diagnostics
Bruno Eschli – Head, IR
Conference Call Participants
Richard Vosser – JPMorgan
Emily Field – Barclays
Sachin Jain – Bank of America
Matthew Weston – UBS
Simon Baker – Redburn
James Quigley – Goldman Sachs
Richard Parkes – BNP
Rajesh Kumar – HSBC
Justin Smith – Bernstein
Benjamin Jackson – Jefferies
Operator
[Starts Abruptly] If you note that the webinar is being recorded. I’d like to inform you that all participants are in listen-only mode, during the call. After the presentation, there will be a question-and-answer session. [Operator Instructions] One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation.
At this time, it’s my pleasure to introduce you to Thomas Schinecker, CEO of Roche Group. Mr. Schinecker, the stage is yours.
Thomas Schinecker
Thank you very much, and hello to everyone, wherever in the world you are. I’m really excited to share with you the results of 2024 for the Roche Group, because I believe they have been — this year has really been an excellent year for us.
So let’s look at the performance. So overall, Group sales was at 7%. The base business, meaning excluding COVID-19, grew even with impressive 9%, pharma 9%, and diagnostics 8%. We saw the last and final impact of COVID-19 sales in — reduction in 2024, so there is no more impact going forward. The final impact was CHF1.1 billion, so exactly in line with the guidance that we gave at the beginning of the year. The LOE impact was CHF1 billion. So slightly better than the guidance we
Read the full article here
